Duell J, Maddocks KJ, Gonzalez-Barca E, Jurczak W, et al. Long-term outcomes from the Phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma. Haematologica 2021 Jul 1. doi: 10.3324/haematol.2020.275958.
PMID: 34196165